Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867035 | 0.86 | SLC7A5 (0.48) | SLC7A5 | |
| SCHEMBL17199754 | 0.86 | GRIK1 (0.31) | GRIK1GRIK2SLC7A5 | |
| SCHEMBL5707690 | 0.86 | SLC7A5 (0.48) | GRIK1GRIK2SLC7A5 | |
| SCHEMBL8679062 | 0.83 | CHRNB2 (0.33) | SLC7A5GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6567069 | 0.83 | BHMT (0.37) | GRIK1GRIK2SLC7A5 | |
| SCHEMBL14486118 | 0.83 | CHRNB2 (0.33) | SLC7A5GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL10527497 | 0.82 | SLC7A5 (0.45) | SLC7A5 | |
| SCHEMBL7676359 | 0.81 | SLC7A5 (0.52) | SLC7A5 | |
| SCHEMBL1674752 | 0.81 | GABRR1 (0.33) | GRIK1GRIK2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL867143 | 0.81 | ALOX15 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186394-B2 | Pharmacological vitreolysis | THROMBOGENICS NV (BE) | 2015-11-17 | — | — | US | claimed |
| US-8834869-B2 | Pharmacological vitreolysis | THROMBOGENICS NV (BE) | 2014-09-16 | — | — | US | claimed |
| US-20130302304-A1 | PHARMACOLOGICAL VITREOLYSIS | THROMBOGENICS NV (BE) | 2013-11-14 | — | — | US | claimed |
| US-20130202613-A1 | PHARMACOLOGICAL VITREOLYSIS | THROMBOGENICS NV (BE) | 2013-08-08 | — | — | US | claimed |
| US-20130195887-A1 | PHARMACOLOGICAL VITREOLYSIS | THROMBOGENICS NV (BE) | 2013-08-01 | — | — | US | claimed |
| US-8460655-B2 | Pharmacological vitreolysis | THROMBOGENICS NV (BE) | 2013-06-11 | — | — | US | claimed |
| US-20090081187-A1 | Liquefying a vitreous and/or inducing posterior vitreous detachment of an eye via microplasmin injection; treating vision defects; preventing or reducing the risk of retinal detachment; catalytic domain of plasmin | THROMB-X NV (BE) | 2009-03-26 | — | — | US | claimed |
| US-20090074739-A1 | non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form ; treating vision defects; preventing or reducing the risk of retinal detachment; catalytic domain of plasmin | THROMB-X NV (BE) | 2009-03-19 | — | — | US | claimed |
| US-20080050356-A1 | Liquefying a vitreous and/or inducing posterior vitreous detachment of an eye via microplasmin injection; treating vision defects; preventing or reducing the risk of retinal detachment | THROMB-X NV (BE) | 2008-02-28 | — | — | US | claimed |
| WO-2023063340-A1 | INFORMATION ACQUISITION DEVICE, PROGRAM, RECOMBINANT VECTOR PRODUCTION METHOD, FISSION YEAST, AND GENE EXPRESSION SUPPRESSING METHOD | 学校法人 久留米大学 | 2023-04-20 | — | — | WO | disclosed |
| US-20220162568-A1 | PORE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| EP-3953369-A1 | PORE | Oxford Nanopore Technologies plc (GB) | 2022-02-16 | — | — | EP | disclosed |
| CN-113677693-A | Hole(s) | 牛津纳米孔科技公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020208357-A1 | PORE | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2020-10-15 | — | — | WO | disclosed |
| EP-1581254-A4 | PHARMACOLOGICAL VITREOLYSIS | THROMB X NV (BE) | 2007-03-28 | — | — | EP | disclosed |
| US-20060275897-A1 | HIV vaccines based on Env of multiple clades of HIV | DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2006-12-07 | — | — | US | disclosed |
| EP-1581254-A2 | PHARMACOLOGICAL VITREOLYSIS | Thromb-X NV (BE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050118158-A1 | Treating or preventing an eye disorder using a composition comprising a truncated plasmin protein comprising a catalytic domain of plasmin (TPCD) | THROMB-X NV (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2004052228-A2 | PHARMACOLOGICAL VITREOLYSIS | THROMB-X NV (BE) | 2004-06-24 | — | — | WO | disclosed |
| US-5006337-A | For treating skin disorders | MARBERT GMBH (DE) | 1991-04-09 | — | — | US | disclosed |